Skip to main content
Erschienen in: Supportive Care in Cancer 4/2018

26.12.2017 | Review Article

Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis

verfasst von: Akira Kuriyama, Koji Endo

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) limits the dose of chemotherapy and reduces patients’ quality of life. Goshajinkigan is a Japanese herbal medicine used to alleviate neuropathy and general pain. A clinical guideline for prevention and management of CIPN stated that the prophylactic efficacy of goshajinkigan against CIPN was inconclusive. We conducted a systematic review to examine whether goshajinkigan prevents CIPN in patients receiving neurotoxic chemotherapy.

Methods

We searched PubMed, EMBASE, Ichushi, and the Cochrane Central Register of Controlled Trials for eligible trials. Randomized controlled trials that examined the efficacy and safety of goshajinkigan for prevention of CIPN were included. Our primary outcomes were incidence of CIPN, response to chemotherapy, and adverse effects. We pooled data using a random effects model.

Results

We analyzed five trials involving a total of 397 patients. When evaluated with Neurotoxicity Criteria of Debiopharm, goshajinkigan was associated with reduced incidence of CIPN of grade ≥ 1 (risk ratio [RR] 0.43; 95% CI, 0.27 to 0.66) and grade 3 (RR 0.42; 95% CI, 0.25 to 0.71), but this beneficial association was not found for grade ≥ 2 of CIPN. Goshajinkigan was not associated with reduced incidence of CIPN when assessed with the National Cancer Institute Common Terminology Criteria for Adverse Events, or improved response to chemotherapy. Goshajinkigan was well tolerated based on one trial.

Conclusions

Goshajinkigan is unlikely to prevent CIPN in patients undergoing neurotoxic chemotherapy. Given the low quality and insufficient amount of the evidence, use of goshajinkigan as standard of care is not currently recommended.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
4.
Zurück zum Zitat Bahar MA, Andoh T, Ogura K, Hayakawa Y, Saiki I, Kuraishi Y (2013) Herbal medicine goshajinkigan prevents paclitaxel-induced mechanical allodynia without impairing antitumor activity of paclitaxel. Evid Based Complement Alternat Med 2013:849754CrossRefPubMedPubMedCentral Bahar MA, Andoh T, Ogura K, Hayakawa Y, Saiki I, Kuraishi Y (2013) Herbal medicine goshajinkigan prevents paclitaxel-induced mechanical allodynia without impairing antitumor activity of paclitaxel. Evid Based Complement Alternat Med 2013:849754CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Gagnier JJ, DeMelo J, Boon H, Rochon P, Bombardier C (2006) Quality of reporting of randomized controlled trials of herbal medicine interventions. Am J Med 119:800 e801–800 e811CrossRef Gagnier JJ, DeMelo J, Boon H, Rochon P, Bombardier C (2006) Quality of reporting of randomized controlled trials of herbal medicine interventions. Am J Med 119:800 e801–800 e811CrossRef
8.
Zurück zum Zitat Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889–894CrossRefPubMed Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889–894CrossRefPubMed
9.
Zurück zum Zitat Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical O (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967CrossRefPubMed Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical O (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967CrossRefPubMed
12.
Zurück zum Zitat Hirayama Y, Sasaki J, Dosaka-Akita H, Ishitani K (2016) Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology. ESMO open 1:e000053CrossRefPubMedPubMedCentral Hirayama Y, Sasaki J, Dosaka-Akita H, Ishitani K (2016) Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology. ESMO open 1:e000053CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Hosokawa A, Ogawa K, Ando T, Suzuki N, Ueda A, Kajiura S, Kobayashi Y, Tsukioka Y, Horikawa N, Yabushita K, Fukuoka J, Sugiyama T (2012) Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. Anticancer Res 32(7):2545–2550PubMed Hosokawa A, Ogawa K, Ando T, Suzuki N, Ueda A, Kajiura S, Kobayashi Y, Tsukioka Y, Horikawa N, Yabushita K, Fukuoka J, Sugiyama T (2012) Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. Anticancer Res 32(7):2545–2550PubMed
15.
Zurück zum Zitat Kajiwara M, Mutaguchi K (2008) Clinical efficacy and tolerability of gosha-jinki-gan, Japanese traditional herbal medicine, in females with overactive bladder. Hinyokika kiyo Acta urologica Japonica 54:95–99PubMed Kajiwara M, Mutaguchi K (2008) Clinical efficacy and tolerability of gosha-jinki-gan, Japanese traditional herbal medicine, in females with overactive bladder. Hinyokika kiyo Acta urologica Japonica 54:95–99PubMed
16.
Zurück zum Zitat Kaku H, Kumagai S, Onoue H, Takada A, Shoji T, Miura F, Yoshizaki A, Sato S, Kigawa J, Arai T, Tsunoda S, Tominaga E, Aoki D, Sugiyama T (2012) Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: a multicenter collaborative study. Exp Ther Med 3(1):60–65. https://doi.org/10.3892/etm.2011.375 CrossRefPubMed Kaku H, Kumagai S, Onoue H, Takada A, Shoji T, Miura F, Yoshizaki A, Sato S, Kigawa J, Arai T, Tsunoda S, Tominaga E, Aoki D, Sugiyama T (2012) Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: a multicenter collaborative study. Exp Ther Med 3(1):60–65. https://​doi.​org/​10.​3892/​etm.​2011.​375 CrossRefPubMed
17.
Zurück zum Zitat Kamei J, Hayashi S-S, Miyata S (2008) Effect of Gosha-jinki-gan on vincristine-induced painful neuropathy in mice. Jpn J Pharm Palliat Care Sci 1:19–24 Kamei J, Hayashi S-S, Miyata S (2008) Effect of Gosha-jinki-gan on vincristine-induced painful neuropathy in mice. Jpn J Pharm Palliat Care Sci 1:19–24
18.
Zurück zum Zitat Kawabata K, Kawajiri H, Takashima T, Nakano T, Mitukawa Y, Kawakami N (2013) P2-043 * reduction of paclitaxel-related peripheral sensory neuropathy by Gosha-jinki-gan or carbon dioxide feet and hand bathing. Ann Oncol 24:ix80CrossRef Kawabata K, Kawajiri H, Takashima T, Nakano T, Mitukawa Y, Kawakami N (2013) P2-043 * reduction of paclitaxel-related peripheral sensory neuropathy by Gosha-jinki-gan or carbon dioxide feet and hand bathing. Ann Oncol 24:ix80CrossRef
19.
Zurück zum Zitat Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, Yamamoto Y, Suzuki S, Asama T, Kamiya K (2011) Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Compl Alternat Med 2011:418481 Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, Yamamoto Y, Suzuki S, Asama T, Kamiya K (2011) Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Compl Alternat Med 2011:418481
20.
Zurück zum Zitat Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H (2013) Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol 72(6):1283–1290. https://doi.org/10.1007/s00280-013-2306-7 CrossRefPubMedPubMedCentral Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H (2013) Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol 72(6):1283–1290. https://​doi.​org/​10.​1007/​s00280-013-2306-7 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151(4):W65–W94CrossRefPubMed Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151(4):W65–W94CrossRefPubMed
23.
Zurück zum Zitat Matsumura Y, Yokoyama Y, Hirakawa H, Shigeto T, Futagami M, Mizunuma H (2014) The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action. Mol Pain 10:61CrossRefPubMedPubMedCentral Matsumura Y, Yokoyama Y, Hirakawa H, Shigeto T, Futagami M, Mizunuma H (2014) The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action. Mol Pain 10:61CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Mizuno K, Kono T, Suzuki Y, Miyagi C, Omiya Y, Miyano K, Kase Y, Uezono Y (2014) Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat. J Pharmacol Sci 125(1):91–98. https://doi.org/10.1254/jphs.13244FP CrossRefPubMed Mizuno K, Kono T, Suzuki Y, Miyagi C, Omiya Y, Miyano K, Kase Y, Uezono Y (2014) Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat. J Pharmacol Sci 125(1):91–98. https://​doi.​org/​10.​1254/​jphs.​13244FP CrossRefPubMed
27.
Zurück zum Zitat Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20(4):767–775. https://doi.org/10.1007/s10147-015-0784-9 CrossRefPubMed Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20(4):767–775. https://​doi.​org/​10.​1007/​s10147-015-0784-9 CrossRefPubMed
30.
Zurück zum Zitat Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848PubMedPubMedCentral Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848PubMedPubMedCentral
34.
Zurück zum Zitat UMIN000021361. Comparing investigation of the curative effect by Goshajinkigan and Pregabalin for -Induced Peripheral Neuropathy. (Accessed as of May 5, 2017). In: Editor (ed)^(eds) Book Comparing investigation of the curative effect by Goshajinkigan and Pregabalin for -Induced Peripheral Neuropathy. (Accessed as of May 5, 2017), City UMIN000021361. Comparing investigation of the curative effect by Goshajinkigan and Pregabalin for -Induced Peripheral Neuropathy. (Accessed as of May 5, 2017). In: Editor (ed)^(eds) Book Comparing investigation of the curative effect by Goshajinkigan and Pregabalin for -Induced Peripheral Neuropathy. (Accessed as of May 5, 2017), City
36.
Zurück zum Zitat Watanabe K, Shimada A, Miyaki K, Hirakata A, Matsuoka K, Omae K, Takei I (2014) Long-term effects of goshajinkigan in prevention of diabetic complications: a randomized open-labeled clinical trial. Evid Based Complement Alternat Med 2014:128726PubMedPubMedCentral Watanabe K, Shimada A, Miyaki K, Hirakata A, Matsuoka K, Omae K, Takei I (2014) Long-term effects of goshajinkigan in prevention of diabetic complications: a randomized open-labeled clinical trial. Evid Based Complement Alternat Med 2014:128726PubMedPubMedCentral
37.
Zurück zum Zitat Yoshida N, Hosokawa T, Ishikawa T, Yagi N, Kokura S, Naito Y, Nakanishi M, Kokuba Y, Otsuji E, Kuroboshi H, Taniwaki M, Taguchi T, Hosoi H, Nakamura T, Miki T (2013) Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. J Oncol 2013:139740CrossRefPubMedPubMedCentral Yoshida N, Hosokawa T, Ishikawa T, Yagi N, Kokura S, Naito Y, Nakanishi M, Kokuba Y, Otsuji E, Kuroboshi H, Taniwaki M, Taguchi T, Hosoi H, Nakamura T, Miki T (2013) Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. J Oncol 2013:139740CrossRefPubMedPubMedCentral
Metadaten
Titel
Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis
verfasst von
Akira Kuriyama
Koji Endo
Publikationsdatum
26.12.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-4028-6

Weitere Artikel der Ausgabe 4/2018

Supportive Care in Cancer 4/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.